Johnson & Johnson

Strategic Intent

Johnson & Johnson is a global healthcare leader focused on the research, development, and manufacturing of pharmaceutical products (Innovative Medicine) and medical technologies (MedTech) following the 2023 spin-off of its consumer health business.

Key Market Signals

• 2025-11: Acquisition of Halda Therapeutics for $3.05B to secure 'hold and kill' tumor technology.
• 2025-04: Completion of $14.6B acquisition of Intra-Cellular Therapies, adding Caplyta to the neuro portfolio.
• 2025-02: U.S. DOJ closed its FCPA investigation into J&J's Brazil operations with no further action.
• 2024-08: Acquisition of V-Wave for $600M to expand MedTech cardiovascular offerings.
• 2024-04: Acquisition of Shockwave Medical for $13.1B, strengthening leadership in heart disease treatment.

Financial Health

• Reported 2025 full-year sales of $94.2 billion, reflecting 6.0% growth over 2024 (Source: https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results)
• 2025 adjusted net earnings reached $26.2 billion with adjusted EPS of $10.79 (Source: https://www.jnj.com/media-center/press-releases/johnson-johnson-reports-q4-and-full-year-2025-results)
• Innovative Medicine segment exceeded $60 billion in annual sales for the first time in 2025 (Source: https://www.investor.jnj.com/financials/sec-filings)

Impact & Compliance

Legal & Risks

Johnson & Johnson faces significant ongoing litigation regarding its talc-based products, with over 67,000 pending lawsuits and multiple billion-dollar verdicts in 2025. The company continues to attempt a global settlement through subsidiary bankruptcy filings, the most recent of which was dismissed

Forensic Audit — 1 findings

• DOJ closed Brazil FCPA probe in Feb 2025, but SEC investigation into the same matter remains ongoing

Classifications

Proprietary Analysis